期刊
IMMUNOLOGIC RESEARCH
卷 42, 期 1-3, 页码 182-196出版社
HUMANA PRESS INC
DOI: 10.1007/s12026-008-8070-9
关键词
Adoptive cell transfer therapy; Artificial antigen presenting cells; Regulatory T cells; Th17 Cells; Central Memory T cells
类别
资金
- NIH [5T32CA101968, 1R01CA120409]
- Cancer Research Training
- Leukemia and Lymphoma Society
Many recent advances in basic cell biology and immunology are a harbinger of progress in adoptive cell therapy (ACT) including (1) the finding that host lymphodepletion enhances engraftment and efficacy, (2) the recognition that in vitro T cell functions may not correlate with in vivo efficacy, and (3) the development of advanced ex vivo culture methods to expand lymphocytes to therapeutically effective numbers. In this article, we focus on the development of artificial antigen presenting cells (aAPCs) in our laboratory and their applicability to augment ACT protocols. We also describe how aAPCs can be used to broaden ACT to treat patients with a wide variety of cancers, chronic infectious diseases, and autoimmune manifestations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据